The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The evolving treatment landscape of SCD
Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, discusses advances in the field of sickle cell disease (SCD), discussing the mechanism of action of drugs such as voxelotor and GBT021601, and highlighting the promise of gene therapy and combination therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer
